首页> 外文期刊>European Journal of Pharmacology: An International Journal >Systemic and local dexamethasone treatments prevent allergic eosinophilia in rats via distinct mechanisms.
【24h】

Systemic and local dexamethasone treatments prevent allergic eosinophilia in rats via distinct mechanisms.

机译:全身和局部地塞米松治疗通过独特的机制防止大鼠过敏性嗜酸性粒细胞增多。

获取原文
获取原文并翻译 | 示例
           

摘要

We have studied the effect of local and systemic treatment with dexamethasone for prevention of the pleural eosinophilia triggered by allergen in actively sensitised Wistar rats. Parallel changes in blood and marrow eosinophil numbers were assessed for comparison. The intrapleural (i.pl.) injection of ovalbumin into ovalbumin-sensitised animals led to a long-lasting pleural fluid eosinophilia which peaked from 24 to 72 h post-challenge. At these time points, there was a significant 2- to 3-fold increase in the blood eosinophil numbers, whereas the bone marrow number of mature eosinophils remained unaltered. Systemic treatment with dexamethasone (0.05-0.5 mg/kg, i.p.) abolished the pleural and blood eosinophilia observed 24 and 48 h post-challenge, also causing a significant reduction in marrow eosinophil numbers. Despite being unable to alter blood and bone marrow eosinophil numbers, the local i.pl. administration of dexamethasone (2.5-10 microg/cavity) inhibited dose dependently the allergen-induced pleural eosinophil influx at 24 h but not at 48 h post-challenge. This treatment also shortened the time course of eosinophil accumulation in the pleural space from the 48 h time point on. We conclude that the effect of systemic but not of local treatment with dexamethasone on allergen-induced eosinophil recruitment is well correlated with the inhibition of eosinophil production in bone marrow. In contrast, low amounts of dexamethasone injected into the pleural space seem to affect locally eosinophil recruitment and survival.
机译:我们研究了地塞米松的局部和全身治疗对预防致敏性Wistar大鼠变应原引发的胸膜嗜酸性粒细胞增多的作用。评估血液和骨髓嗜酸性粒细胞数目的平行变化以进行比较。向卵白蛋白致敏的动物胸膜内(i.pl.)注射卵白蛋白导致持久的胸膜液嗜酸性粒细胞增多,其在攻击后24至72小时达到峰值。在这些时间点,血液中的嗜酸性粒细胞数量显着增加了2到3倍,而成熟嗜酸性粒细胞的骨髓数量保持不变。地塞米松(0.05-0.5 mg / kg,腹腔注射)全身性治疗消除了攻击后24和48 h观察到的胸膜和血液嗜酸性粒细胞增多症,也导致了骨髓嗜酸性粒细胞数目的显着减少。尽管不能改变血液和骨髓嗜酸性粒细胞的数量,但是当地的i.pl。地塞米松(2.5-10微克/腔)的给药在激发后24 h而不是在激发后48 h剂量依赖性地抑制了变应原诱导的胸膜嗜酸性粒细胞流入。从48小时开始,这种治疗还缩短了嗜酸性粒细胞在胸膜间隙中积累的时间。我们得出结论,地塞米松全身治疗而非局部治疗对变应原诱导的嗜酸性粒细胞募集的影响与骨髓中嗜酸性粒细胞产生的抑制作用密切相关。相反,向胸膜腔注射少量地塞米松似乎影响局部嗜酸性粒细胞的募集和存活。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号